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Knowledge regarding the mechanisms of the IL17–IL23 pathway and its role in spondy-
loarthritis (SpA) has been pivotal to the development of IL-17 blockade in patients with 
axial SpA. Previously, only anti-TNF has proven to be clinically efficacious in patients 
with active disease, despite non-steroidal anti-inflammatory drugs and physiotherapy. 
However, up to 50% fail to achieve a clinically significant response. Secukinumab, a 
fully humanized monoclonal antibody targeting IL-17A, has recently been approved for 
use in patients with active ankylosing spondylitis. Clinical studies and current issues 
surrounding the use of secukinumab will be discussed.
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iNtrODUctiON
Ankylosing spondylitis (AS) is a chronic inflammatory disease predominantly affecting the axial 
skeleton and possibly the peripheral joints and entheses with a major impact on quality of life (1). 
It is the prototype of several inter-related inflammatory arthritides, referred to as spondyloarthritis 
(SpA), and grouped together as it shares a number of common genetic, pathogenic, and phenotypic 
features (1).
Non-steroidal anti-inflammatory drugs (NSAIDs) and physiotherapy including stretching exer-
cises remain the initial first-line treatment for patients (2, 3). Disease-modifying anti-rheumatic 
drugs are not effective in patients with axial involvement and patients with continual disease activ-
ity, despite NSAIDs and physiotherapy would benefit from anti-TNF (4–7). Although dramatic 
improvements in disease activity and physical function are usually expected, up to 40–50% of these 
patients fail to have a clinically significant response (2, 3). Moreover, anti-TNF cannot maintain 
long-term remission, with most patients flaring after stopping the treatment (8). Anti-TNF can 
effectively control inflammation and therefore can prevent joint destruction (9). However, it does 
not halt new bone formation (10). This indicates other potentially important pathogenic pathways 
are involved in SpA.
Treatment goals are now focused on remission or achievement of low disease activity (11). 
The number of drugs available for patients with SpA that are formally available for clinical use is 
significantly less than other rheumatic diseases such as rheumatoid arthritis (RA). While there is 
proven efficacy in a number of biologic therapies for RA, studies evaluating tocilizumab, abatacept, 
and rituximab have been disappointing in SpA (12–15). There is increasing evidence that IL-17A 
blockade can be effective in patients with active SpA of which this review will focus on.
PAtHOPHYsiOLOGY OF spA AND iL17–iL23 AXis
Previously, the pathogenesis has centered on description of the Th1 pathway and TNF-alpha (16). 
Knowledge regarding the mechanisms of the IL17–IL23 pathway has increased with genetic, 
tABLe 1 | AsAs response criteria for clinical trials (26).
response criteria components included in the response criteria
ASAS20 At least 20% improvement from baseline and an 
absolute improvement from baseline of at least 1 U 
(on scale 0–10) in at least three out of four ASAS 
assessment domains, and no worsening >1 U in the 
remaining one out of the four domains
 1. Patient global assessment
 2. Spinal pain
 3. Physical function from BASFI
 4. Inflammation/morning stiffness
ASAS40 At least 40% improvement from baseline and an 
absolute improvement from baseline of at least 2 U 
(on scale 0–10) in at least three out of four ASAS 
assessment domains, and no worsening >2 U in the 
remaining one out of the four domains
 1. Patient global assessment
 2. Spinal pain
 3. Physical function from BASFI
 4. Inflammation/morning stiffness
ASAS partial remission A score of <2 in each of the four ASAS assessment 
domains
ASAS, Assessment of Spondyloarthritis International Society; BASFI, Bath Ankylosing 
Spondylitis Functional Index.
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experimental models and functional data suggesting that it 
plays a crucial role in SpA (16, 17). First evidence came from 
genetic studies that showed protective polymorphisms in the 
IL-23 receptor gene (rs11209026, Arg381Gln) for AS (18) by 
impairing function of Th17 cells to produce IL-17 through the 
IL-23-dependent pathway. In addition, animal models have 
demonstrated that HLA-B27 misfolding and homodimer forma-
tion can trigger IL-23 and IL-17 production (19). Furthermore, 
upregulation of IL-17 expression due to expansion of Th17 cells is 
seen in HLA-B27 transgenic mice (20). Animal studies have also 
shown that IL-23 overexpression can induce a SpA-like disease 
with development of enthesitis (21) and bone formation (22).
The numbers of IL-17-producing cells are also elevated in 
the circulation and target tissues in AS patients (23), and the 
frequency of IL17+ CD4+ T cells is increased in early axial 
SpA patients, with or without MRI evidence of sacroiliitis (24). 
Moreover, macrophages of AS patients can produce higher levels 
of IL-23 with increased IL17-producing innate immune cells 
(25, 26).
iL17 iNHiBitiON iN spA—cLiNicAL 
stUDies
Due to previous preclinical data and its proven efficacy in psoria-
sis and psoriatic arthritis (27), a number of monoclonal antibod-
ies have been developed to target IL-17A in SpA. IL-17A is the 
prototype in the IL-17 family of cytokines. To date, IL-17A and 
IL-17F are the most studied, although the latter is less implicated 
in autoimmunity, partly due to significantly reduced signaling 
triggered by IL-17F (28). Available agents so far include secuki-
numab (anti-IL17A), ixekizumab (anti-IL17A), and brodalumab 
(anti-IL17RA) for example (29). To date, only secukinumab 
is clinically approved, while the others are still under evalua-
tion. Secukinumab is a fully anti-interleukin 17A monoclonal 
antibody, highly specific to the human immunoglobulin G1k 
(IgG1k) subclass. The current recommended dosing for axial SpA 
is weekly loading dose of 150 mg subcutaneously for 1 month, 
followed by monthly 150 mg of subcutaneous injections.
A Phase 2 open-label proof-of-concept study using secuki-
numab in 37 AS patients was conducted in Netherlands and 
Germany over 28 weeks (30). In this study, two intravenous doses 
of secukinumab 10 mg/kg, 3 weeks apart, was administered. Like 
other pivotal anti-TNF trials (4–7), the primary outcome was the 
proportion of patients achieving ASAS20 [Table 1; (31)] and was 
achieved in 59% of patients at 6 weeks.
This paved way to Phase 3 clinical studies of secukinumab 
in AS (MEASURE 1, n = 371 and MEASURE 2, n = 219) (32). 
Unlike the pivotal anti-TNF trials (4–7), not all of the patients 
were anti-TNF naïve (only 71 and 61% of patients were anti-TNF 
naïve in MEASURE 1 and MEASURE 2, respectively).
On the one hand, in MEASURE 1, patients received intra-
venous loading doses (10 mg/kg) at 0, 2, and 4 weeks, followed 
by either monthly subcutaneous secukinumab, at doses of 150 
or 75 mg, vs. placebo. The primary outcome (ASAS20) at Week 
16 was achieved by 61% in the 150  mg arm and 60% in the 
75 mg arm. ASAS40 was achieved by 49 and 34%, respectively, 
while ASAS partial remission was 15 and 16%, respectively. 
On the other hand, in MEASURE 2, patients received weekly 
subcutaneous loading doses of either 150 or 75 mg for 1 month 
followed by monthly administration vs. placebo. ASAS20 
response at Week 16 was achieved in 61% of patients receiv-
ing the 150  mg compared to 41% in those receiving 75  mg. 
ASAS40 response rates were 43 and 31%, respectively, while 
partial remission was achieved in 14 and 15%, respectively. On 
the basis of superior outcomes in majority of the domains in 
the 150 mg dosing, this was the recommended dosing for SpA. 
One reasonable explanation to the better outcomes at 75  mg 
dosing in MEASURE 1 compared to MEASURE 2 study was 
due to the initial intravenous loading dose received by patients 
in MEASURE 1 (32).
Anti-tNF Naïve vs. tNF Non-responders
As mentioned previously, around 30% were not anti-TNF naïve. 
Although inclusion criteria such as disease activity and failure of 
first-line therapy with NSAIDs were comparable to pivotal anti-
TNF trials (4–7), patients with spinal ankylosis were excluded in 
both MEASURE 1 and MEASURE 2. At Week 16, response rates 
for anti-TNF were higher than anti-TNF inadequate responders 
in MEASURE 1 (Figure 1A) and MEASURE 2 (Figure 1B) (32). 
However, up to 60% of anti-TNF inadequate responders had also 
achieved ASAS20 response by 52 weeks (33).
extra-Articular Manifestations
Although there is good evidence of its efficacy in both axial 
and peripheral musculoskeletal manifestations, as well as extra-
articular manifestations such as psoriasis (24), the effectiveness 
on uveitis is less clear. To date, secukinumab is not efficacious in 
patients with inflammatory bowel disease (34), and it is unclear 
AB
FiGUre 1 | (A) ASAS20 and ASAS40 response rates (MEASURE 1) for secukinumab 150 mg dosing. (B) ASAS20 and ASAS40 response rates (MEASURE 2) for 
secukinumab 150 mg dosing.
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if it would induce the condition. However, studies of Phase 2 
and Phase 3 clinical trials of psoriasis, psoriatic arthritis, and 
AS patients who received secukinumab indicated that inflam-
matory bowel disease incidences or flares were infrequently 
reported (35).
efficacy of secukinumab at 2 Years
Recently, longer term 2-year data were available, demonstrating 
that secukinumab provided sustained improvements in signs 
and symptoms of AS, with improved physical function regardless 
of anti-TNF status (36). In MEASURE 2, both 75 and 150-mg 
dosing achieved similar ASAS20 and ASAS40. The proportion 
of patients in both doses that achieved ASAS20 and ASAS40 was 
72 and 48%, respectively, by 2 years. In those that continued the 
trial, the proportion of anti-TNF inadequate responders and anti-
TNF naïve patients that achieved ASAS20 and ASAS40 response 
were similar at 2 years as well. Similarly, sustained improvements 
through 2 years including disease activity, pain, physical function, 
and fatigue as well as general and AS-specific measures of quality 
of life were demonstrated (37).
radiographic Progression
To date, radiographic data are only available in SpA patients with 
radiographic sacroiliitis, up to 2 years for secukinumab (38–40), 
which are short to evaluate radiographic progression since the 
process is slow. In MEASURE 1, both 150 and 75 mg doses were 
pooled together as there were no major clinical differences. Of the 
371 patients, 80% of patients showed no radiographic progression 
[modified stoke ankylosing spondylitis spine score (mSASSS) 
change ≤0] in patients receiving secukinumab over 104  weeks 
(40). Factors that contributed to progression were similar to 
anti-TNF studies such as males, baseline syndesmophytes, and 
elevated CRP levels at baseline (40). The authors commented 
that changes in mSASSS through 2 years may be lower than those 
reported in earlier observational and interventional studies in AS, 
but the question whether this therapy may reduce bone formation 
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remains (40). In fact, the controversy of bone formation from anti-
TNF in axial SpA has not been fully resolved. While earlier studies 
on adalimumab, infliximab, and etanercept failed to demonstrate 
reduction in radiographic progression in axial SpA (10, 41, 42), 
further studies have indicated that radiographic progression could 
be delayed if anti-TNF was given early, or for a long period of time, 
presumably because the inflammation specifically causing bone 
formation has been suppressed (43, 44). Although the proportion 
of patients who had radiographic progression in MEASURE 1 
was lower than the anti-TNF studies (10, 41, 42), there was no 
control arm. Only head-to-head studies evaluating anti-TNF and 
secukinumab can answer this question. Moreover, there is a need 
at least to compare secukinumab with a historical control as well 
as having longer term studies to answer this question.
safety information
As expected, patients who received secukinumab had more 
infections compared to placebo (30 vs. 12% in MEASURE 1 and 
32 vs. 27% in MEASURE 2) (32). Exposure adjusted incidence 
rates of serious adverse events were 73.5 and 59.4 events per 100 
patient-years among patients receiving 150 and 75 mg, respec-
tively, in MEASURE 1, compared to 60.5 and 89.1, respectively, 
for MEASURE 2. The most common side effect is nasophar-
yngitis followed by headaches. Candida infection, which could 
theoretically increase with IL-17A inhibition, was reported in 
three cases, with pooled adjusted incidence of candidiasis in 
secukinumab-treated patients across the two studies of 0.9 events 
per 100 patient-years of exposure. Crohn’s disease was an adverse 
event in five patients, while uveitis was reported in five patients 
vs. two patients receiving placebo. Major adverse cardiac events 
for the entire treatment period of both studies were 0.4 per 100 
patient-years, consistent with incidence rates in other SpA (32). 
Of the results so far, there is no increased reactivation or cases 
of tuberculosis. No reports of increased suicidality were seen in 
those treated with secukinumab, which was observed previously 
in trials of brodalumab in psoriasis patients. Four malignant or 
unspecified tumors were reported. Immunogenicity was also low 
with no antidrug antibodies detected (32).
issUes OF iL17 iNHiBitiON
A number of issues remain unresolved. There are no data on 
the efficacy of secukinumab in non-radiographic SpA. It is also 
unclear whether a loading dose of weekly 150 mg subcutaneous 
injections is necessary. Although secukinumab is recommended 
at dose of 150 mg, it would be interesting to characterize patients 
that would respond to 75 mg and to evaluate the clinical out-
comes between the two dosages beyond 2 years. More evaluation 
on patients who did not respond to anti-TNF would be neces-
sary to establish if secukinumab is superior to switching class of 
anti-TNF (45). Logically, from our experience in RA, we would 
expect switching to a different class of medication to be more 
efficacious.
In addition, reactivation of TB should be monitored, since 
anti-TNF poses this potential risk. So far, in  vitro testing with 
peripheral blood mononuclear cells infected with Mycobacterium 
tuberculosis treated with anti-TNF and IL-17A inhibition showed 
that anti-IL-17A treatment in vitro did not reverse M. tuberculosis 
dormancy in a human granuloma model (46). Long-term clini-
cal data would be necessary to prove this theoretical advantage. 
Specifically for areas such as Asia, where TB is common, this 
question is important to evaluate.
Like that of anti-TNF, the debate about whether co-medi-
cations are necessary, even in cases of peripheral predominant 
disease, should be evaluated. Although present data show very 
little development of anti-secukinumab antibodies, it remains to 
be seen whether patients will develop secondary non-response; 
however, the data currently show low immunogenicity rates. It 
is also unknown whether secukinumab would be effective in 
patients with spinal ankylosis. It is also unclear how long it takes 
for patients to flare after stopping secukinumab, an observation 
already well known with anti-TNF (8).
Finally, structural progression in AS, characterized mainly 
by new bone formation, can lead to ankylosis of the spine. The 
question whether secukinumab can halt bone formation remains 
unanswered.
cUrreNt ONGOiNG stUDies
Ongoing studies are evaluating some of these issues. The 
5-year data for MEASURE 2 should be available in the future. 
Another study is evaluating the optimal dosing of secukinumab 
by comparing dosing at 300 vs. 150  mg (http://ClinTrials.gov 
number NCT02008916) each receiving loading dose 10  mg/kg 
initially. This is considering that the current indicated dosing for 
psoriasis and those with psoriatic arthritis who were anti-TNF 
non-responders is recommended at 300 mg. Another study will 
evaluate the need for initial loading dose (NCT02159053). Non-
radiographic axial SpA with or without loading dose 150 mg is 
currently being evaluated (NCT02696031). Finally, the effects of 
NSAID tapering in patients with secukinumab (NCT02763046) 
will also be studied.
OtHer PrOMisiNG tHerAPies
Other therapy that is important to consider is that of ustekinumab 
(47) and tofacitinib (48). Promising results for tofacitinib was 
recently presented, with Phase 2 results showing significant dif-
ference compared to placebo in terms of disease activity, function, 
and mobility (48).
PrActicAL APPLicAtiONs ON WHicH 
tHerAPY tO Use—ANti-tNF Or iL-17A 
BLOcKADe?
At present, anti-TNF is still the preferred first-line biologic 
agent for patients with active axial SpA, and either switching to 
another anti-TNF or to IL-17A blockade is equally acceptable if 
there is primary or secondary non-response. However, there are 
instances where IL-17A may be preferred, for example, in patients 
with higher risk of tuberculosis or in cases with psoriasis with 
high burden of peripheral arthritis, although extensive psoriasis 
is not routinely seen in patients with axial SpA. In cases of history 
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cONcLUsiON
It is currently an exciting time for biologic therapies available in 
SpA. Secukinumab has now emerged as an alternative therapy for 
patients with SpA. Despite a number of unanswered questions 
still, current preliminary results appear promising.
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